Related Experiment Video
Updated: Jul 11, 2025

A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
Association between the β-blocker use and patients with sepsis: a cohort study
Qilin Yang1, Tianyu Kong1, Ziping Bao1
1Department of Critical Care, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Objective:
This study aimed to assess whether β-blockers are associated with mortality in patients with sepsis.
Method:
We conducted a retrospective cohort study of patients with sepsis using the Medical Information Market for Intensive Care (MIMIC)-IV and the emergency intensive care unit (eICU) databases. The primary outcome was the in-hospital mortality rate. The propensity score matching (PSM) method was adopted to reduce confounder bias. Subgroup and sensitivity analyses were performed to test the stability of the conclusions.
Results:
We included a total of 61,751 patients with sepsis, with an overall in-hospital mortality rate of 15.3% in MIMIC-IV and 13.6% in eICU. The inverse probability-weighting model showed that in-hospital mortality was significantly lower in the β-blockers group than in the non-β-blockers group [HR = 0.71, 95% CI: 0.66-0.75, p < 0.001 in MIMIC-IV, and HR = 0.48, 95% CI: 0.45-0.52, p < 0.001 in eICU]. In subgroups grouped according to sex, age, heart rate, APSIII, septic shock, and admission years, the results did not change.
Conclusion:
β-blocker use is associated with lower in-hospital mortality in patients with sepsis, further randomized trials are required to confirm this association.
Related Concept Videos
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers

